MarcS, I have not followed Dr. P's LH activiti
Post# of 154147
(Total Views: 605)
Posted On: 08/14/2021 10:02:01 PM
MarcS,
I have not followed Dr. P's LH activities with great detail, but I believe he, both here and abroad, is using his cytokine profiling assay to design treatment plans based on available therapeutics.
It feels to me that he has a tool and for which he is seeking a purpose. Some have argued the same about Cytodyn, but obviously I feel very differently about Leronlimab than I do the IncellKINE assay.
It is certainly presumptuous of me, but I nonetheless have concerns that treatment regimens designed based on his assay and his machine learning description of activated monocytes have not, at least publicly, been validated. He may very well be correct, but descriptions of immune profiles correlating with symptoms may or may not be adequately predictive of appropriate treatments.
There are other competing explanations for LH symptoms (Epstein Barr virus reactivation). Dr. BP may have additional non-published data, but difficult to know whether his treatments will address root causes.
Lots of resources thrown at elevated IL-6 and TNF-alpha, but to did only very marginal success with tocilizumab for IL-6 in a subset of patients.
Cytodyn still has a lot of detail to fully show the impact of Leronlimab on LH, but at least they have conducted blinded, controlled trials.
Without a controlled study, in spite of the IncellKINE assay, the treatment regimens for these LH patients are likely to generate as much criticism as acclaim.
I have not followed Dr. P's LH activities with great detail, but I believe he, both here and abroad, is using his cytokine profiling assay to design treatment plans based on available therapeutics.
It feels to me that he has a tool and for which he is seeking a purpose. Some have argued the same about Cytodyn, but obviously I feel very differently about Leronlimab than I do the IncellKINE assay.
It is certainly presumptuous of me, but I nonetheless have concerns that treatment regimens designed based on his assay and his machine learning description of activated monocytes have not, at least publicly, been validated. He may very well be correct, but descriptions of immune profiles correlating with symptoms may or may not be adequately predictive of appropriate treatments.
There are other competing explanations for LH symptoms (Epstein Barr virus reactivation). Dr. BP may have additional non-published data, but difficult to know whether his treatments will address root causes.
Lots of resources thrown at elevated IL-6 and TNF-alpha, but to did only very marginal success with tocilizumab for IL-6 in a subset of patients.
Cytodyn still has a lot of detail to fully show the impact of Leronlimab on LH, but at least they have conducted blinded, controlled trials.
Without a controlled study, in spite of the IncellKINE assay, the treatment regimens for these LH patients are likely to generate as much criticism as acclaim.
(15)
(0)